Latest News on RIGL

Financial News Based On Company


Advertisement
Advertisement

American Century Entities Exceed 5% Ownership Threshold in Rigel Pharmaceuticals

https://kalkinemedia.com/us/news/announcements/american-century-entities-exceed-5-ownership-threshold-in-rigel-pharmaceuticals
American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have reported exceeding the 5% ownership threshold in Rigel Pharmaceuticals, Inc. common stock. The Schedule 13G filing, dated November 16, 2026, details their beneficial ownership stakes as of September 30, 2026, indicating that these shares were acquired and held in the ordinary course of business.

An ETF trust reports a passive stake above 5% in Rigel Pharmaceuticals (RIGL).

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-rigel-pharmaceuticals-inc-passive-investment-disclosure--cb822c2555e2.html
American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have reported passive stakes in Rigel Pharmaceuticals (RIGL). The ETF Trust beneficially owned 991,858 common shares, or 5.3%, as of September 30, 2026. The latter three entities in the ownership chain each reported beneficial ownership of 1,043,966 shares, or 5.6%, with sole voting and dispositive power.

An investment manager reports a passive stake of 1.536 million Rigel Pharmaceuticals (RIGL) shares.

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-a-rigel-pharmaceuticals-inc-amended-passive-investment-d-fe0b018a1573.html
Armistice Capital, LLC and its managing member, Steven Boyd, have reported a passive beneficial ownership of 1,536,000 common shares of Rigel Pharmaceuticals, Inc. (RIGL), which represents an 8.22% stake in the company. Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares. The Master Fund retains the right to receive dividends and proceeds from sales.

Morgan Stanley reports a passive stake above 5% in Rigel Pharmaceuticals (RIGL).

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-rigel-pharmaceuticals-inc-passive-investment-disclosure--d9907ea0a266.html
Morgan Stanley and Morgan Stanley Capital Services LLC have reported passive beneficial ownership stakes in Rigel Pharmaceuticals Inc. (RIGL) as of September 30, 2026. Morgan Stanley holds 6.5% of the class with 1,212,656 shares, while Morgan Stanley Capital Services LLC holds 5.6% with 1,040,643 shares. These filings indicate that the securities were acquired and are held in the ordinary course of business, without the purpose of changing or influencing the control of the issuer.

Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Aren't As Good As They Appear

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/rigel-pharmaceuticals-nasdaqrigl-earnings-arent-as-good-as-t
Rigel Pharmaceuticals' recent earnings report, while showing a strong statutory profit, is analyzed as potentially misleading due to a high accrual ratio and an unusual one-off tax benefit. The article suggests that the company's free cash flow is significantly weaker than its reported profit, and without the tax benefit, future statutory profits may drop, leading to a potentially overly positive impression of the company's financial health. Investors are advised to look beyond the headline profit figure and consider these underlying factors.
Advertisement

Form SCHEDULE 13G RIGEL PHARMACEUTICALS Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+RIGEL+PHARMACEUTICALS+Filed+by%3A+STATE+STREET+CORP/27320375.html
STATE STREET CORPORATION has filed a Schedule 13G form indicating its beneficial ownership of Rigel Pharmaceuticals Inc. common stock. The filing shows that State Street Corporation holds 879,862 shares, representing 4.7% of the class. This statement was filed due to an event occurring on September 30, 2026.

State Street reports a Rigel Pharmaceuticals (RIGL) stake with shared voting power over 858,066 shares.

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-rigel-pharmaceuticals-inc-passive-investment-disclosure--1c09dbdeb82c.html
State Street Corporation has reported a 4.7% beneficial ownership stake in Rigel Pharmaceuticals Inc. (RIGL), totaling 879,862 shares. The report, filed as a Schedule 13G, indicates shared voting power over 858,066 shares and shared dispositive power over 879,862 shares, with zero sole voting or dispositive power. Subsidiaries like SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company are identified in the filing.

Weekly Recap: Revenue rises, EPS falls and product sales are mixed

https://www.tradingview.com/news/tradingview:b53e4d0334355:0-weekly-recap-revenue-rises-eps-falls-and-product-sales-are-mixed/
Rigel Pharmaceuticals (NASDAQ:RIGL) reported a 16.5% year-over-year revenue increase to $80.9 million in the third quarter, though adjusted earnings per share declined. The company's new product VEPPANU generated $6.6 million in its initial six weeks, and Rigel expects to complete Phase 2 enrollment for R289 by the end of 2026. Cantor Fitzgerald maintained a Neutral rating on RIGL while raising its price target to $47.

Missed Out On Rigel Pharmaceuticals' Run? Here's What Changed

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/missed-out-on-rigel-pharmaceuticals-run-heres-what-changed
Rigel Pharmaceuticals has seen a 21.7% return over the past year, largely due to its strategic shift around the newly licensed oral PROTAC, VEPPANU, for ESR1-mutated breast cancer. The company's Q3 2026 results showed revenue growth but net income compression, reflecting the challenges and opportunities of its portfolio expansion. While the stock has seen a significant gain, its current trading price of US$42.05 is still below the analyst consensus Fair Value, which anticipates continued growth from commercialization efforts and a diversified drug franchise.

Citigroup maintains Rigel Pharmaceuticals at Buy, raises price target to $86 from $83

https://www.tradingview.com/news/tradingview:451365882ef9b:0-citigroup-maintains-rigel-pharmaceuticals-at-buy-raises-price-target-to-86-from-83/
Citigroup has maintained its "Buy" rating for Rigel Pharmaceuticals and increased its price target from $83 to $86. This new price target suggests a potential upside of 116.9% from the stock's closing price on November 6th. Investors can find more details on price targets and analyst recommendations on TradingView's platform.
Advertisement

Key facts: Rigel Posts $80.9M Q3 Revenue; Cantor Raises Price Target to $47

https://www.tradingview.com/news/tradingview:a0d9d94cef4d5:0-key-facts-rigel-posts-80-9m-q3-revenue-cantor-raises-price-target-to-47/
Rigel Pharmaceuticals (RIGL) reported Q3 2026 revenue of $80.9 million, with net product sales increasing 13% year over year to $72.3 million. Despite a rise in TAVALISSE and REZLIDHIA sales, net income fell to $13.2 million. Following these results, Cantor Fitzgerald maintained a Neutral rating on RIGL but raised its price target from $43 to $47.

Rigel Pharmaceuticals Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:9164032b1094b:0-rigel-pharmaceuticals-q3-earnings-call-highlights/
Rigel Pharmaceuticals reported record quarterly product sales in Q3 2026, driven by the launch of breast cancer treatment VEPPANU, despite a decline in net income due to increased spending on research and commercialization. The company sees VEPPANU and experimental treatment R289 as key growth drivers, with plans to present updated R289 data in December and start a registrational study in 2027. Rigel also narrowed its full-year total revenue outlook while expecting continued positive net income.

Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ...

https://sg.finance.yahoo.com/news/rigel-pharmaceuticals-inc-rigl-q3-191433632.html
Rigel Pharmaceuticals Inc (RIGL) reported record net product sales of $72.3 million in Q3 2026, a 13% year-over-year increase, driven by the strong launch of VEPPANU. The company achieved a net income of $13.2 million for the quarter and anticipates full-year profitability, while also advancing its R289 pipeline asset. Despite some declines in GAVRETO sales and increased expenses, the company expressed confidence in its diversified commercial portfolio and future growth prospects.

Rigel Pharmaceuticals (RIGL) Misses Q3 EPS by 25c

https://www.streetinsider.com/Earnings/Rigel+Pharmaceuticals+%28RIGL%29+Misses+Q3+EPS+by+25c/27301802.html
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q3 EPS of $0.70, missing analyst estimates of $0.95 by $0.25. Despite the EPS miss, the company's revenue for the quarter came in at $80.9 million, surpassing the consensus estimate of $79.99 million.

Rigel Pharmaceuticals Q3FY26 Results: Net product sales up 13% YoY to $72.3M

https://scanx.trade/stock-market-news/companies/rigel-pharmaceuticals-raises-fy26-sales-guidance-290m-295m/55459352
Rigel Pharmaceuticals reported record net product sales of $72.3 million for Q3FY26, a 13% year-over-year increase, driven by $6.6 million from its new product, Vepanu. The company narrowed its full-year revenue guidance to $290-$295 million, still below analyst consensus estimates. Strong performance from Tavalisse and Rezlidhia contributed to growth, alongside ongoing advancements in its R289 pipeline.
Advertisement

Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates

https://ca.finance.yahoo.com/news/rigel-pharmaceuticals-rigl-misses-q3-000006508.html
Rigel Pharmaceuticals (RIGL) reported Q3 earnings of $0.65 per share, falling short of the Zacks Consensus Estimate of $0.87 per share, and lower than $1.46 per share a year ago. Despite the earnings miss, the company's revenues of $80.89 million surpassed the consensus estimate by 3.35%. Rigel currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.

Rigel to present updated Phase 1b data on R289 and TAVALISSE at ASH 2026 meeting

https://pluang.com/en/news-feed/rigel-umumkan-presentasi-data-fase-1b-r289-pada-pasien-mds-risiko-rendah
Rigel Pharmaceuticals will present updated Phase 1b data on its dual IRAK1/4 inhibitor, R289, for lower-risk myelodysplastic syndrome (MDS) at the 2026 ASH Annual Meeting, highlighting potential reductions in transfusion dependence. Additionally, the company will feature three poster presentations on TAVALISSE (fostamatinib) for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), including real-world safety and effectiveness data. These presentations underline Rigel's ongoing progress in developing treatments for various hematologic disorders and cancer.

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

https://www.prnewswire.com/news-releases/rigel-announces-oral-presentation-of-phase-1b-data-for-r289-in-patients-with-lower-risk-mds-at-the-68th-american-society-of-hematology-annual-meeting-and-exposition-302929341.html
Rigel Pharmaceuticals, Inc. announced an upcoming oral presentation of updated Phase 1b data for its dual IRAK1/4 inhibitor, R289, in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS) at the 68th American Society of Hematology (ASH) Annual Meeting. The presentation will include efficacy and safety data from the dose expansion phase, focusing on the reduction of transfusion dependence. Additionally, three poster presentations will highlight data for TAVALISSE® (fostamatinib) in patients with chronic ITP and warm autoimmune hemolytic anemia (wAIHA).

What Rigel Pharmaceuticals Holders Saw Early

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/what-rigel-pharmaceuticals-holders-saw-early
Rigel Pharmaceuticals shareholders saw a 62.8% return over the past year. A year ago, there were conflicting views on the company's valuation, with bullish forecasts citing clinical expansion and bearish ones highlighting regulatory pressure and drug concentration. The company's recent acquisition of VEPPANU supports the bullish case for a richer oncology portfolio, but Q2 2026 results showed a decline in revenue and net income, indicating that profitability must keep pace with pipeline expansion and significant in-licensing commitments.

Rigel Pharmaceuticals, Inc. (RIGL) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/RIGL/seasonality/
The article displays a seasonal returns chart for Rigel Pharmaceuticals, Inc. (RIGL), showing the average monthly price return between 2016 and 2026. It also includes current stock information, such as the real-time price and overnight trading activity.
Advertisement

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

https://www.tradingview.com/news/prnewswire:2a0884876a7f9:0-rigel-announces-conference-call-and-webcast-to-report-third-quarter-2026-financial-results/
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the results and provide a business update. The webcast will be accessible from Rigel's Investor Relations section and archived for 90 days.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

https://finance.yahoo.com/healthcare/articles/rigel-announces-conference-call-webcast-120500136.html
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The event will be accessible via webcast from the Investor Relations section of the company's website.

Rigel Pharmaceuticals, Inc. Estimates – NASDAQ:RIGL

https://www.tradingview.com/symbols/NASDAQ-RIGL/financials-estimates/
The article provides an overview of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) financial estimates available on TradingView. It highlights features for exploring reported financial data and analyst estimates across various statements and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time for both annual and quarterly data.

Rigel Pharmaceuticals shifts focus to oncology with new product VEPPANU targeting $1B breast cancer market.

https://pluang.com/en/news-feed/rigel-pharmaceuticals-mengubah-castoffs-big-pharma-menjadi-mesin-pertumbuhan
Rigel Pharmaceuticals is transitioning its strategic focus to oncology, introducing its new drug VEPPANU in the U.S. to target the $1 billion market for ESR1-mutated breast cancer. Despite not yet seeing VEPPANU's early sales reflected in current forecasts, Rigel's stock is trading at a discount compared to sector averages, supported by strong sales growth and high profit margins from its existing business. Investors are keen on the upcoming Q3 results for updates on key products and VEPPANU's initial market performance.

Missed Rigel Pharmaceuticals' Rally? Here's What Early Buyers Saw

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rigl/rigel-pharmaceuticals/news/missed-rigel-pharmaceuticals-rally-heres-what-early-buyers-s
Rigel Pharmaceuticals recently secured a global license for VEPPANU, an FDA-approved drug for advanced breast cancer, which fueled a 58.6% return over the past year. This article examines the contrasting bullish and bearish "Narratives" that investors would have weighed to justify a purchase, highlighting how the VEPPANU deal aligned with the bullish outlook on portfolio expansion despite a recent dip in Q2 2026 revenue and net income. It concludes by noting that the current stock price already reflects confidence in these new oncology deals, suggesting that current buyers are betting on new products justifying rising in-licensing and clinical costs while maintaining profitability.
Advertisement

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

https://www.prnewswire.com/news-releases/rigel-highlights-new-gavreto-pralsetinib-data-across-ret-fusion-positive-cancers-in-oral-and-poster-presentations-at-esmo-congress-2026-302912054.html
Rigel Pharmaceuticals, Inc. announced new data from clinical trials of GAVRETO (pralsetinib) demonstrating robust and durable activity across various RET fusion-positive cancers. The findings, presented at ESMO Congress 2026, include a 53% overall response rate in solid tumors and positive first-line clinical outcomes and quality-of-life improvements in RET fusion-positive NSCLC and thyroid cancer. These results support pralsetinib's potential as a broad therapy for RET fusion-positive solid tumors.

A cancer drug produced responses in 53% of patients with several types of cancer

https://www.stocktitan.net/news/RIGL/rigel-highlights-new-gavreto-pralsetinib-data-across-ret-fusion-1rpybtm54tgo.html
Rigel Pharmaceuticals announced positive clinical data for GAVRETO (pralsetinib) in RET fusion-positive cancers, demonstrating a 53% overall response rate in a pooled analysis of various solid tumors. The drug also showed an 81.3% response rate in thyroid cancer and improved patient-reported quality of life in NSCLC. These findings reinforce GAVRETO's potential as a treatment option for these specific cancer types.

Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history

https://au.finance.yahoo.com/quote/RIGL/
This Yahoo Finance page provides a detailed overview of Rigel Pharmaceuticals, Inc. (RIGL), including its current stock price, recent performance, key financial metrics, and historical data. As of close on October 13, the stock was trading at $47.14, down 3.42%. The page also offers various valuation measures, profitability highlights, and balance sheet information.

H.C. Wainwright Sticks to Their Buy Rating for Rigel (RIGL)

https://www.theglobeandmail.com/investing/markets/stocks/RIGL-Q/pressreleases/4986914/h-c-wainwright-sticks-to-their-buy-rating-for-rigel-rigl/
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating for Rigel (RIGL) with a price target of $85.00. Pantginis is a 5-star analyst with a 25.8% average return. Rigel reported quarterly revenue of $78.7 million and a net profit of $17.29 million for the quarter ending June 30.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

https://syvnews.com/online_features/press_releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_8ff3b8d3-eaff-582f-95ec-a21ab66be0f3.html
Rigel Pharmaceuticals, Inc. announced the granting of 35,275 restricted stock units to 18 non-executive employees under its Inducement Plan. These grants were made as an inducement for employment, in accordance with NASDAQ Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting each year.
Advertisement

Trading Systems Reacting to (RIGL) Volatility

https://news.stocktradersdaily.com/news_release/150/Trading_Systems_Reacting_to_RIGL_Volatility_100526093803_1791250683.html
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is experiencing volatility, with weak near-term sentiment potentially preceding shifts in mid and long-term outlook. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights resistance testing and an exceptional risk-reward short setup for the stock.

18 new employees at Rigel receive stock awards vesting over four years.

https://www.stocktitan.net/news/RIGL/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-tu6yl9zwntoz.html
Rigel Pharmaceuticals (NASDAQ: RIGL) granted 35,275 restricted stock units to 18 new non-executive employees as an inducement to employment. These awards will vest over four years, with 25% of the grant vesting annually. This action was approved by Rigel's Board Compensation Committee and is in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel Pharmaceuticals Inc. Advanced Charts | RI2

https://www.barrons.com/market-data/stocks/ri2/interactive-chart?countrycode=de&iso=xfra
This article provides advanced chart information and financial data for Rigel Pharmaceuticals Inc. (RI2) on the Frankfurt market. It includes details such as the current price, analyst ratings, key financial metrics like market value and P/E ratio, and a brief company profile. The data shows a "Sell" average score from analysts and highlights the company's focus on immunology, oncology, and immune-oncology.

Rigel Pharmaceuticals Inc. Research & Ratings | RI2

https://www.barrons.com/market-data/stocks/ri2/research-ratings?countrycode=de&iso=xfra&mod=quotes
This Barron's article provides research and ratings for Rigel Pharmaceuticals Inc. (RI2), a clinical-stage biotechnology company. It includes analyst ratings with an average price target, key financial metrics, company overview, and historical and estimated earnings data. The company focuses on developing targeted drugs for immunology, oncology, and immune oncology.

Rigel Pharmaceuticals Inc. Company & People | RI2

https://www.barrons.com/market-data/stocks/ri2/company-people?countrycode=de&iso=xfra&mod=quotes
Rigel Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing drugs for immunology, oncology, and immune oncology. The company's stock, RI2, is traded on the Frankfurt market and has an average analyst rating of "Sell." Key financial metrics and corporate details are provided, including executive leadership and contact information.
Advertisement

Rigel Pharmaceuticals grants 35,275 restricted stock units to 18 new employees as an inducement.

https://pluang.com/en/news-feed/rigel-pharmaceuticals-beri-hak-saham-karyawan-baru
Rigel Pharmaceuticals has granted 35,275 restricted stock units to 18 new, non-executive employees as an inducement, with the stock units vesting over four years. This initiative aims to attract and retain talent to support the company's growth in developing therapies for hematologic disorders and cancer. The announcement provides context for the health sector's market activity, with a snapshot showing that 66 out of 100 priced health-sector US stocks rose on October 2, 2026.

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302896740.html
Rigel Pharmaceuticals, Inc. announced inducement grants consisting of 35,275 restricted stock units to 18 non-executive employees. These grants, vesting over four years, were approved by the Compensation Committee and are intended to induce employment, in accordance with NASDAQ Listing Rule 5635(c)(4). Rigel is a biotechnology company focused on hematologic disorders and cancer based in South San Francisco, California.

Rigel Pharmaceuticals, Inc. (RIGL) Options Chain - Yahoo Finance

https://ca.finance.yahoo.com/quote/RIGL/options/?date=1797552000&straddle=false&type=all
The article displays the options chain for Rigel Pharmaceuticals, Inc. (RIGL) on Yahoo Finance. It indicates that there are currently no calls or puts in the money, and the options data is delayed by 15 minutes. The stock closed at $47.89 on September 24 and remained unchanged after hours.

H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $85

https://www.moomoo.com/news/post/75951182/hc-wainwright-maintains-rigel-pharmaceuticals-riglus-with-buy-rating-maintains
H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US) and maintained its target price at $85. This indicates continued confidence in the company's financial outlook and market performance by the analyst firm.

Trading the Move, Not the Narrative: (RIGL) Edition

https://news.stocktradersdaily.com/news_release/22/Trading_the_Move,_Not_the_Narrative:_RIGL_Edition_090426085001_1788569401.html
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to suggest trading strategies. It highlights strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels, and provides specific entry, target, and stop-loss points for position, momentum, and risk-hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Advertisement

Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month

https://tradersunion.com/news/companies/show/3184479-rigel-itp-awareness-campaign/
Rigel Pharmaceuticals has partnered with the Platelet Disorder Support Association (PDSA_ITP) for an ITP awareness campaign this month. The initiative is part of #ITPawareness month, aiming to increase understanding and engagement within the immune thrombocytopenia community. This campaign follows Rigel's recent U.S. launch of VEPPANU, an FDA-approved therapy, and its Q2 2026 financial reporting.

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

https://www.marketbeat.com/instant-alerts/rigel-pharmaceuticals-nasdaqrigl-rating-increased-to-hold-at-zacks-research-2026-08-19/
Zacks Research upgraded Rigel Pharmaceuticals (NASDAQ:RIGL) from a "strong sell" to a "hold" rating, while other analysts maintained or raised their price targets. The company recently reported strong quarterly earnings, significantly beating analyst expectations for both EPS and revenue. Institutional investors hold a substantial stake in Rigel Pharmaceuticals.

HC Wainwright Analysts Increase Earnings Estimates for RIGL

https://www.marketbeat.com/instant-alerts/hc-wainwright-analysts-increase-earnings-estimates-for-rigl-2026-08-18/
HC Wainwright analysts have increased their Q3 2026 earnings per share estimate for Rigel Pharmaceuticals (NASDAQ:RIGL) to $0.99 from $0.68, maintaining a "Buy" rating and an $85 price target. This revision follows Rigel's strong quarterly results, where EPS of $0.88 significantly beat the $0.09 consensus and revenue of $78.7 million surpassed expectations of $55.27 million. The firm also provided optimistic full-year earnings projections through 2030, while overall analyst sentiment remains mixed with an average "Hold" rating and a $59.00 consensus price target.

Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $49

https://www.moomoo.com/news/post/74799906/piper-sandler-maintains-rigel-pharmaceuticals-riglus-with-hold-rating-raises
Piper Sandler has reiterated its Hold rating on Rigel Pharmaceuticals (RIGL.US) and increased its price target to $49. This adjustment reflects the firm's continued evaluation of the company's financial and market position.

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

https://finance.yahoo.com/markets/stocks/articles/rigel-pharmaceuticals-rigl-stock-sees-050858751.html
Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu as a new growth engine and have raised their price target for RIGL, although execution risk for both products remains a key factor for investors to monitor. The fair value adjustment also reflects changes in revenue growth assumptions, net profit margin expectations, and future P/E multiples.
Advertisement

(RIGL) Price Dynamics and Execution-Aware Positioning

https://news.stocktradersdaily.com/news_release/16/RIGL_Price_Dynamics_and_Execution-Aware_Positioning_081526051602_1786785362.html
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific institutional trading strategies (Position, Momentum Breakout, and Risk Hedging). The analysis also provides multi-timeframe signal strengths and support/resistance levels for RIGL.

Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-a-rigel-pharmaceuticals-inc-amended-passive-investment-d-3de39d71792d.html
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared voting and dispositive power over these securities.

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

https://www.gurufocus.com/news/9035419/rigl-maintained-by-hc-wainwright-co-price-target-raised-to-85
HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF Value™ of $26.86, and insider activity shows net selling. The company's GF Score™ is 73/100, indicating fair financial health but notable weaknesses in profitability and valuation.

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

https://www.prnewswire.com/news-releases/rigel-announces-availability-of-veppanu-vepdegestrant-for-patients-with-erher2--esr1-mutated-advanced-or-metastatic-breast-cancer-302850316.html
Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the United States. This drug is the first and only FDA-approved PROTAC and is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. The company emphasizes VEPPANU's novel mechanism of action and its potential as an important new treatment option, supported by Rigel's existing oncology infrastructure and patient support programs.

Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake

https://www.stocktitan.net/sec-filings/RIGL/schedule-13g-a-rigel-pharmaceuticals-inc-amended-passive-investment-d-6cff956f8788.html
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 9.9% beneficial ownership stake in Rigel Pharmaceuticals, Inc. (RIGL). This ownership amounts to 1,843,504 shares of common stock, based on 18,679,864 shares outstanding as of July 30, 2026. The filing indicates shared voting and dispositive power over these shares among the Soleus entities and Guy Levy.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement